PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.\', \'Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan. sato-daisaku@pmda.go.jp.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s40264-021-01104-9
?:hasPublicationType
?:journal
  • Drug safety
is ?:pmid of
?:pmid
?:pmid
  • 34347278
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.447
?:rankingScore_hIndex
  • 112
is ?:relation_isRelatedTo_publication of
?:title
  • Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34347278>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34347278>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all